Combined hepatocellular-cholangiocarcinoma: A population-level analysis of an uncommon primary liver tumor

Liver Transplantation

Volumn 20, Issue 8, 2014, Pages 952-959

  Garancini, Mattia ^a   Goffredo, Paolo ^a   Pagni, Fabio ^a   Romano, Fabrizio ^a   Roman, Sanziana ^b   Sosa, Julie Ann ^b   Giardini, Vittorio ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLACK PERSON; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; FEMALE; HEPATOCELLULAR CHOLANGIOCARCINOMA; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MARRIED PERSON; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RACE; RISK FACTOR; SINGLE (MARITAL STATUS); SURVIVAL TIME; TUMOR INVASION; BILE DUCT NEOPLASMS; CANCER REGISTRY; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; INCIDENCE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNITED STATES;

AGED; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84905560576     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23897     Document Type: Article

References (43)

1. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW,. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 2006; 36: 892-897.
2. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002; 94: 2040-2046.
3. Allen RA, Lisa JR,. Combined liver cell and bile duct carcinoma. Am J Pathol 1949; 25: 647-655.
4. Lee CC, Wu CY, Chen JT, Chen GH,. Comparing combined hepatocellular- cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology 2002; 49: 1487-1490.
5. Chok KS, Ng KK, Cheung TT, Yuen WK, Poon RT, Lo CM, Fan ST,. An update on long-term outcome of curative hepatic resection for hepatocholangiocarcinoma. World J Surg 2009; 33: 1916-1921.
6. Kim W, Lee JH, Kim YJ, Yoon JH, Suh KS, Lee KU, et al. Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma [in Korean]. Korean J Gastroenterol 2007; 49: 158-165.
7. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 2009; 16: 623-629.
8. Kassahun WT, Hauss J,. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62: 1271-1278.
9. Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, Zhou LX,. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2007; 6: 161-165.
10. Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19: 2869-2876.
11. Lee CH, Hsieh SY, Chang CJ, Lin YJ,. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013; 28: 122-127.
12. Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011; 45: 69-75.
13. Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE,. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 2008; 1: 43-47.
14. Groeschl RT, Turaga KK, Gamblin TC,. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol 2013; 107: 608-612.
15. National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov. Accessed February 2013.
16. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S,. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000. http://www.amazon.com/ International-Classification-Diseases-Oncology-ICD-O/dp/9241545348/ref=sr-1-1?s= books&ie=UTF8&qid=1399598833&sr=1-1&keywords= Fritz+A+International+Classification+of+Diseases+for+Oncology.
17. National Cancer Institute. About the SEER registries. http://seer.cancer.gov/registries/index.html. Accessed February 2013.
18. National Cancer Institute. Glossary of statistical terms. http://seer.cancer.gov/cgi-bin/glossary/glossary.pl#letter-s. Accessed February 2013.
19. Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology 2012; 56: 1804-1816.
20. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M,. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92: 2374-2383.
21. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-287.
22. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33: 283-287.
23. Brenner H,. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131-1135.
24. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L,. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17 (suppl 2): S44-S57.
25. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
26. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006; 10: 987-998.
27. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 11: 693-699.
28. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086.
29. Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993; 166: 768-771.
30. Meyer CG, Penn I, James L,. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637.
31. Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Bäckman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-822.
32. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458.
33. Schwartz JJ, Hutson WR, Gayowski TJ, Sorensen JB,. Liver transplantation for cholangiocarcinoma. Transplantation 2009; 88: 295-298.
34. Maganty K, Levi D, Moon J, Bejarano PA, Arosemena L, Tzakis A, Martin P,. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci 2010; 55: 3597-3601.
35. Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, Harnois DM,. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant 2010; 10: 1263-1267.
36. Sapisochin G, Fidelman N, Roberts JP, Yao FY,. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011; 17: 934-942.
37. Olthoff KM, Millis JM, Rosove MH, Goldstein LI, Ramming KP, Busuttil RW,. Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg 1990; 125: 1261-1268.
38. Haug CE, Jenkins RL, Rohrer RJ, Auchincloss H, Delmonico FL, Freeman RB, et al. Liver transplantation for primary hepatic cancer. Transplantation 1992; 53: 376-382.
39. Moreno González E, Gõmez R, García I, González-Pinto I, Loinaz C, Ibañez J, et al. Liver transplantation in malignant primary hepatic neoplasms. Am J Surg 1992; 163: 395-400.
40. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 2002; 236: 602-611.
41. National Cancer Institute. SEER quality improvement. http://seer.cancer. gov/qi. Accessed February 2013.
42. Harlan LC, Hankey BF,. The Surveillance, Epidemiology, and End-Results Program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003; 21: 2232-2233.
43. Yu JB, Gross CP, Wilson LD, Smith BD,. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park) 2009; 23: 288-295.